UNSPSC 51453018: Piperazine sulfate

This classification denotes an antihelminthic agent with the molecular formula C4H10N2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8493J9B36. The term dipiperazine sulfate is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule piperazine sulfate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE SULFATE remains US FDA's Preferred Term for this commodity. Piperazine sulfate bears US NLM identifiers UMLS ID C0892285 and NCI Concept Code C81514. SMILES: C1CNCCN1.OS(=O)(=O)O.

UNSPSC 51453018 Piperazine sulfate is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement activity. The recent opportunities tagged to this code—naloxone procurement, direct-to-manufacturer prescription programs, medical and first aid supplies, and generic pharmaceuticals through cooperative purchasing—involve finished pharmaceutical products and pharmacy benefit administration rather than piperazine sulfate as a raw chemical ingredient. The code shows a significant mismatch between its nominal scope and actual procurement activity.

State and local issuing bodies using this code span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across Minnesota and Oregon). Recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly delivery requirements (due July 26, 2023); the City of Tampa's sheltered-market IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 and a 5 percent bid discount for certified Small Local Business Enterprises (due March 13, 2026); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities, with proposals due March 26, 2026; and the Texas Health and Human Services Commission's RFI regarding vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (due April 3, 2026). The geographic spread includes Florida, Texas, Minnesota, and Oregon, with activity concentrated in state health agencies and cooperative purchasing vehicles rather than dispersed city and county procurement offices. Given the code's nominal scope and the absence of piperazine sulfate references in any recent opportunity, this Commodity code presents little relevant procurement opportunity for vendors in that product category.